Literature DB >> 26138035

Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.

Mirjam Baiter1, Gerold Schuler, Arndt Hartmann, Regine Schneider-Stock, Lucie Heinzerling.   

Abstract

BACKGROUND: BRAF mutation frequencies in melanoma subtypes have clinical implications and offer pathogenetic clues.
OBJECTIVES: To characterize BRAF mutation status in melanoma of unknown primary (MUP) patients, in histological melanoma subtypes and by localization of primary tumors.
METHODS: In 179 patients with stage IV metastatic melanoma, BRAF mutation status, histological subtype and localization of primary (except for 29 MUP patients) were analyzed.
RESULTS: BRAF mutations were found in 44.3%, of which 80.5% were BRAF V600E and 19.5% showed non-V600E BRAF mutations. BRAF mutation frequency depended on histological subtype (57.4% superficial spreading melanoma, 54.7% nodular melanoma, 11.1% mucosal melanoma, 28.6% acral lentiginous melanoma) and concerning non-V600E BRAF mutations on localization of primary. In MUP the BRAF mutation pattern resembled superficial spreading and nodular melanomas.
CONCLUSION: BRAF mutation frequencies depend on histological subtype and localization of primary melanoma. Non-V600E BRAF mutations mostly occur in patients with primaries on 'head and neck' as well as 'trunk' but not on 'extremities'.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26138035     DOI: 10.1159/000381849

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  5 in total

1.  Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.

Authors:  Michael Lattanzi; Yesung Lee; Danny Simpson; Una Moran; Farbod Darvishian; Randie H Kim; Eva Hernando; David Polsky; Doug Hanniford; Richard Shapiro; Russell Berman; Anna C Pavlick; Melissa A Wilson; Tomas Kirchhoff; Jeffrey S Weber; Judy Zhong; Iman Osman
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

2.  Which melanoma patient carries a BRAF-mutation? A comparison of predictive models.

Authors:  Thomas Eigentler; Zeinab Assi; Jessica C Hassel; Lucie Heinzerling; Hans Starz; Mark Berneburg; Jürgen Bauer; Claus Garbe
Journal:  Oncotarget       Date:  2016-06-14

3.  Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.

Authors:  Tim Schaefer; Imke Satzger; Ralf Gutzmer
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

Review 4.  Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date.

Authors:  Amélie Boespflug; Julie Caramel; Stephane Dalle; Luc Thomas
Journal:  Ther Adv Med Oncol       Date:  2017-05-29       Impact factor: 8.168

5.  BRAF fusions identified in melanomas have variable treatment responses and phenotypes.

Authors:  Jacqueline A Turner; Judson G T Bemis; Stacey M Bagby; Anna Capasso; Betelehem W Yacob; Tugs-Saikhan Chimed; Robert Van Gulick; Hannah Lee; Richard Tobin; John J Tentler; Todd Pitts; Martin McCarter; William A Robinson; Kasey L Couts
Journal:  Oncogene       Date:  2018-09-25       Impact factor: 8.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.